Vanguard Group Inc. Has $6.07 Billion Holdings in Becton, Dickinson and Company $BDX

Vanguard Group Inc. increased its position in Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the third quarter, HoldingsChannel reports. The firm owned 32,455,790 shares of the medical instruments supplier’s stock after acquiring an additional 147,041 shares during the period. Vanguard Group Inc. owned 0.11% of Becton, Dickinson and Company worth $6,074,750,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BDX. Phillips Wealth Planners LLC boosted its position in shares of Becton, Dickinson and Company by 2.7% in the third quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock worth $430,000 after buying an additional 58 shares during the period. Pallas Capital Advisors LLC boosted its position in Becton, Dickinson and Company by 9.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 7,215 shares of the medical instruments supplier’s stock worth $1,350,000 after acquiring an additional 608 shares during the period. State of New Jersey Common Pension Fund D grew its stake in Becton, Dickinson and Company by 3.0% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 98,941 shares of the medical instruments supplier’s stock valued at $18,519,000 after acquiring an additional 2,839 shares in the last quarter. Berkshire Asset Management LLC PA acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $208,000. Finally, GF Fund Management CO. LTD. lifted its position in shares of Becton, Dickinson and Company by 12.3% in the third quarter. GF Fund Management CO. LTD. now owns 7,892 shares of the medical instruments supplier’s stock worth $1,477,000 after purchasing an additional 864 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 2,463 shares of company stock worth $501,530 over the last 90 days. Insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BDX shares. Citigroup lowered their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Wells Fargo & Company dropped their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 10th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. lowered their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Finally, Zacks Research downgraded Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Stock Down 1.0%

BDX stock opened at $175.95 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The company has a 50-day moving average of $198.55 and a two-hundred day moving average of $192.32. The stock has a market capitalization of $50.10 billion, a price-to-earnings ratio of 28.70, a price-to-earnings-growth ratio of 2.30 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $185.02.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.